Navigation Links
EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease
Date:7/7/2009

WATERTOWN, Mass., July 7 /PRNewswire/ --

    WHAT:           EnVivo Pharmaceuticals to share results from its Ib/IIa
                    trial in Alzheimer's disease patients with its
                    nicotinic alpha-7 agonist EVP-6124.

    WHEN:           Wednesday, July 15, 2009.

    WHERE:          Alzheimer's Association 2009 International Conference
                    on Alzheimer's Disease (ICAD) in Vienna, Austria.

    WHO:            Dana Hilt, MD, senior vice president, clinical
                    development and chief medical officer, EnVivo
                    Pharmaceuticals.

    ADDITIONAL:     EVP-6124 is EnVivo's novel alpha-7 nicotinic
                    acetylcholine receptor agonist currently in development
                    for Alzheimer's disease and cognitive dysfunction
                    associated with schizophrenia.  In this trial, safety
                    and effects on cognition of EVP-6124 were tested in
                    Alzheimer's patients already on long term treatment
                    with acetylcholine esterase inhibitors.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase 1 studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for Schizophrenia). For more information about EnVivo, visit www.envivopharma.com.


'/>"/>
SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries
2. Startech Environmental Advises Shareholders to Take No Action in Response to Friendly LRL Tender Offer
3. Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others
4. Ronald McDonald House Charities(R) (RMHC(R)) and McDonalds(R) Seek Inspiring Stories Through New Share.Give.Hope. Campaign
5. Shared Race, Social Group Seem to Help People Relate
6. Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th to Discuss Future Strategy
7. Sally Field Shares Her Osteoporosis Story on EmpowHer
8. Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders
9. AlphaRx Shareholder Update
10. Seroquels First- and Second-Line Patient Share Has Grown Since Last Years Analysis of Prescribing Trends in Bipolar Disorder
11. Arcadia Resources Responds to Share Price Volatility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology: